Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
78%(7 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_3
5
45%
Ph phase_1
4
36%
Ph phase_4
2
18%

Phase Distribution

4

Early Stage

0

Mid Stage

7

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 3Large-scale testing
5(45.5%)
Phase 4Post-market surveillance
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(1)
Other(1)

Detailed Status

Completed9
Suspended1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (36.4%)
Phase 35 (45.5%)
Phase 42 (18.2%)

Trials by Status

completed982%
suspended19%
terminated19%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials
NCT04854512Phase 3

Investigational Study of Delayed Release Metformin

Suspended
NCT05151146Phase 1

A Phase 1 Study of ANJ900 Chinese Healthy Subjects

Completed
NCT04064073Phase 1

Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study)

Completed
NCT01864174Phase 4

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Completed
NCT02791490Phase 3

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

Completed
NCT01204775Phase 3

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Completed
NCT01434186Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Completed
NCT02252965Phase 4

Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes

Completed
NCT01619059Phase 3

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Completed
NCT01525225Phase 1

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Terminated
NCT02220218Phase 1

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11